{"success":true,"data":{"pressRelease":{"id":"158748","rtpr_id":"nBw8Kd4tSa-20261001","ticker":"ABCL","exchange":"NASDAQ","all_tickers":["ABCL"],"title":"AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026","author":"Business Wire","published_at":"2026-10-01T20:05:00.109Z","article_body":"AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026\n\nAbCellera\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54611167&newsitemid=20260930581206&lan=en-US&anchor=AbCellera&index=1&md5=b96053fd15b1797d82421cb3c06f4184)\n(Nasdaq: ABCL) will announce its third quarter 2026 financial results on\nMonday, November 9, 2026, and hold an earnings conference call at 3:00 p.m.\nPacific Time (5:00 p.m. Eastern Time) the same day.\n\nA live audio webcast of the earnings conference may be accessed through a link\nthat will be posted on AbCellera’s Investor Relations website\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.abcellera.com%2Foverview%2Fdefault.aspx&esheet=54611167&newsitemid=20260930581206&lan=en-US&anchor=AbCellera%26%238217%3Bs+Investor+Relations+website&index=2&md5=fc599dfca595638a1d55e4a1c6e689eb)\n. A replay will be available through the same link following the conference\ncall.\n\nAbout AbCellera Biologics Inc.\n\nAbCellera\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54611167&newsitemid=20260930581206&lan=en-US&anchor=AbCellera&index=3&md5=9c3ba841052fe89b018617bcc90ce210)\n(Nasdaq: ABCL) is a clinical-stage biotechnology company focused on\ndiscovering and developing first-in-class antibody-based medicines in the\nareas of endocrinology, women’s health, immunology, oncology, and more. For\nmore information, please visit www.abcellera.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54611167&newsitemid=20260930581206&lan=en-US&anchor=www.abcellera.com&index=4&md5=76dfc2c53c8fbea52e2fbe462480bd4f)\n.\n\nAbCellera Forward-looking Statements\n\nThis document contains forward-looking statements, including statements made\npursuant to the safe harbor provisions of the Private Securities Litigation\nReform Act of 1995. The forward-looking statements are based on management’s\nbeliefs and assumptions and on information currently available to management.\nAll statements contained in this document other than statements of historical\nfact are forward-looking statements, including statements regarding our\nability to develop, commercialize and achieve market acceptance of our current\nand planned products and services, our research and development efforts, and\nother matters regarding our business strategies, use of capital, results of\noperations and financial position, plans, objectives for future operations,\nand the evaluation of our available liquidity to execute on our strategy\n(including our ability to access our reimbursement based R&D government\ncontributions). The use of certain data derived from cross-study comparisons\nare not based on any head-to-head clinical trials. Cross-study comparisons are\ninherently limited and may suggest misleading similarities and differences and\nare presented for informational purposes. In some cases, you can identify\nforward-looking statements by the words “may,” “will,” “could,”\n“would,” “should,” “expect,” “intend,” “plan,”\n“anticipate,” “believe,” “estimate,” “predict,” “project,”\n“potential,” “continue,” “ongoing” or the negative of these terms\nor other comparable terminology, although not all forward-looking statements\ncontain these words.\n\nThese statements involve risks, uncertainties and other factors that may cause\nactual results, levels of activity, performance, or achievements to be\nmaterially different from the information expressed or implied by these\nforward-looking statements. These risks, uncertainties, other factors, and\ndefinition of our business metrics are described under “Risk Factors,”\n“Management’s Discussion and Analysis of Financial Condition and Results\nof Operations” and elsewhere in the documents we file with the Securities\nand Exchange Commission from time to time. We caution you that forward-looking\nstatements are based on a combination of facts and factors currently known by\nus and our projections of the future, about which we cannot be certain. As a\nresult, the forward-looking statements may not prove to be accurate. The\nforward-looking statements in this document represent our views as of the date\nhereof. We undertake no obligation to update any forward-looking statements\nfor any reason, except as required by law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930581206/en/\n(https://www.businesswire.com/news/home/20260930581206/en/)\n\nInquiries \n\nMedia: Tiffany Chiu; media@abcellera.com (mailto:media@abcellera.com) ,\n+1(236)521-6774\n\nPartnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com\n(mailto:partnering@abcellera.com) , +1(604)559-9005\n\nInvestor Relations: Peter Ahn; ir@abcellera.com (mailto:ir@abcellera.com) ,\n+1(778)729-9116\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw8Kd4tSa-20261001","title":"AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026","author":"Business Wire","ticker":"ABCL","created":"2026-10-01T20:05:00.109Z","tickers":["ABCL"],"exchange":"NASDAQ","article_body":"AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026\n\nAbCellera\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54611167&newsitemid=20260930581206&lan=en-US&anchor=AbCellera&index=1&md5=b96053fd15b1797d82421cb3c06f4184)\n(Nasdaq: ABCL) will announce its third quarter 2026 financial results on\nMonday, November 9, 2026, and hold an earnings conference call at 3:00 p.m.\nPacific Time (5:00 p.m. Eastern Time) the same day.\n\nA live audio webcast of the earnings conference may be accessed through a link\nthat will be posted on AbCellera’s Investor Relations website\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.abcellera.com%2Foverview%2Fdefault.aspx&esheet=54611167&newsitemid=20260930581206&lan=en-US&anchor=AbCellera%26%238217%3Bs+Investor+Relations+website&index=2&md5=fc599dfca595638a1d55e4a1c6e689eb)\n. A replay will be available through the same link following the conference\ncall.\n\nAbout AbCellera Biologics Inc.\n\nAbCellera\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54611167&newsitemid=20260930581206&lan=en-US&anchor=AbCellera&index=3&md5=9c3ba841052fe89b018617bcc90ce210)\n(Nasdaq: ABCL) is a clinical-stage biotechnology company focused on\ndiscovering and developing first-in-class antibody-based medicines in the\nareas of endocrinology, women’s health, immunology, oncology, and more. For\nmore information, please visit www.abcellera.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.abcellera.com&esheet=54611167&newsitemid=20260930581206&lan=en-US&anchor=www.abcellera.com&index=4&md5=76dfc2c53c8fbea52e2fbe462480bd4f)\n.\n\nAbCellera Forward-looking Statements\n\nThis document contains forward-looking statements, including statements made\npursuant to the safe harbor provisions of the Private Securities Litigation\nReform Act of 1995. The forward-looking statements are based on management’s\nbeliefs and assumptions and on information currently available to management.\nAll statements contained in this document other than statements of historical\nfact are forward-looking statements, including statements regarding our\nability to develop, commercialize and achieve market acceptance of our current\nand planned products and services, our research and development efforts, and\nother matters regarding our business strategies, use of capital, results of\noperations and financial position, plans, objectives for future operations,\nand the evaluation of our available liquidity to execute on our strategy\n(including our ability to access our reimbursement based R&D government\ncontributions). The use of certain data derived from cross-study comparisons\nare not based on any head-to-head clinical trials. Cross-study comparisons are\ninherently limited and may suggest misleading similarities and differences and\nare presented for informational purposes. In some cases, you can identify\nforward-looking statements by the words “may,” “will,” “could,”\n“would,” “should,” “expect,” “intend,” “plan,”\n“anticipate,” “believe,” “estimate,” “predict,” “project,”\n“potential,” “continue,” “ongoing” or the negative of these terms\nor other comparable terminology, although not all forward-looking statements\ncontain these words.\n\nThese statements involve risks, uncertainties and other factors that may cause\nactual results, levels of activity, performance, or achievements to be\nmaterially different from the information expressed or implied by these\nforward-looking statements. These risks, uncertainties, other factors, and\ndefinition of our business metrics are described under “Risk Factors,”\n“Management’s Discussion and Analysis of Financial Condition and Results\nof Operations” and elsewhere in the documents we file with the Securities\nand Exchange Commission from time to time. We caution you that forward-looking\nstatements are based on a combination of facts and factors currently known by\nus and our projections of the future, about which we cannot be certain. As a\nresult, the forward-looking statements may not prove to be accurate. The\nforward-looking statements in this document represent our views as of the date\nhereof. We undertake no obligation to update any forward-looking statements\nfor any reason, except as required by law.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260930581206/en/\n(https://www.businesswire.com/news/home/20260930581206/en/)\n\nInquiries \n\nMedia: Tiffany Chiu; media@abcellera.com (mailto:media@abcellera.com) ,\n+1(236)521-6774\n\nPartnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com\n(mailto:partnering@abcellera.com) , +1(604)559-9005\n\nInvestor Relations: Peter Ahn; ir@abcellera.com (mailto:ir@abcellera.com) ,\n+1(778)729-9116\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-01T20:05:00.182390192Z","server_sent_at_ms":1790885100182},"received_at":"2026-10-01T20:05:00.233Z","source_url":"https://www.businesswire.com/news/home/20260930581206/en/"},"analysis":{"id":"147371","press_release_id":"158748","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"AbCellera (Nasdaq: ABCL) will report third quarter 2026 financial results on Monday, November 9, 2026.\n\nAn earnings conference call is scheduled for 3:00 p.m. Pacific Time the same day, with a live audio webcast available via the company's Investor Relations website and a replay posted afterward.\n\nThis is a scheduling notice only and contains no financial results or business updates.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar item only -- ABCL Q3 2026 earnings set for November 9; suppress until results."},"keyFigures":{},"namedEntities":{"people":[{"name":"Tiffany Chiu","role":"Media contact"},{"name":"Murray McCutcheon, Ph.D.","role":"Partnering contact"},{"name":"Peter Ahn","role":"Investor Relations contact"}],"products":[],"companies":[{"name":"AbCellera Biologics Inc.","ticker":"ABCL"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine earnings-date announcement with no financial results, guidance, or business developments disclosed."},"tickerRelevance":{"others":[],"primary":"ABCL"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap-clinical-stage-biotech","eventGravity":"earnings-date-scheduling-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"AbCellera (Nasdaq: ABCL) will report third quarter 2026 financial results on Monday, November 9, 2026.\n\nAn earnings conference call is scheduled for 3:00 p.m. Pacific Time the same day, with a live audio webcast available via the company's Investor Relations website and a replay posted afterward.\n\nThis is a scheduling notice only and contains no financial results or business updates.","key_figures":{},"named_entities":{"people":[{"name":"Tiffany Chiu","role":"Media contact"},{"name":"Murray McCutcheon, Ph.D.","role":"Partnering contact"},{"name":"Peter Ahn","role":"Investor Relations contact"}],"products":[],"companies":[{"name":"AbCellera Biologics Inc.","ticker":"ABCL"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-01T20:05:03.904Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap-clinical-stage-biotech","eventGravity":"earnings-date-scheduling-notice","issuerAuthored":true}},"durationMs":3659,"modelName":"glm-5.3-flashx"}}